|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 14:03
|
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
|
|
|
Conference Call Today at 8:30 a.m. Eastern TimeQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025.
Fourth Quarter and Full Year 2025 Financial Results
Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively
HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively
CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively
Gross margins of 85% for the fourth quarter and 86% for the full year
Fourth quarter net loss of $1.9 million and full year net income of $2.7 million
Non-GAAP positive adjusted EBITDA for the fourth quarter and full year of $2.4 million and $25.1 million, respectively
Repurchased 628,572 common...
|
|
|
|
|
12.02.26 - 14:06
|
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025.
Conference Call Information
To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.
Event Date: Thursday, February 26, 2026
Time: 8:30 AM Eastern Time
Participant Numbers:
Toll Free: 1-877-407-3982
International: 1-201-493-6780
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&tp_key=15ec7bd15cA replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website here.
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cance...
|
|
|
21.01.26 - 22:03
|
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025.
The grants, in the form of Restricted Stock Units (RSUs), totaled 36,250 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The RSUs were granted on January 2, 2026 and one-third of the RSUs will vest on the first anniversary of the grant date with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The RSUs are subject to the employee's continued employment with Delcath on each vesting date.
The above-described awards were granted in a...
|
|
|
|
|
09.01.26 - 14:09
|
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025.
Preliminary Fourth Quarter and Full-Year 2025 Financial Results (unaudited)
Total fourth quarter and full year revenue expected to be approximately $20.7 million and $85.2 million, respectively
HEPZATO KIT™ fourth quarter and full year revenue expected to be approximately $19.0 million and $78.8 million, respectively
CHEMOSAT® fourth quarter and full year revenue expected to be approximately $1.7 million and $6.4 million, respectively
628,572 common shares repurchased for $6.0 million through December 31, 2025 under the approved $25.0 million Share Buyback Program
As of December 31, 2025, the Company had approximately $91.0 million of cash and short-term investments ...
|
|
|
|
|
|
|
|
|
|
|
20.11.25 - 22:03
|
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time to time, subject to market conditions. The repurchase program does not have an expiration date.
“The share repurchase program reflects our confidence in Delcath's long-term growth prospects and our commitment to creating shareholder value,” said Gerard Michel, Chief Executive Officer of Delcath Systems. “We believe the current share price does not fully reflect our commercial progress, future development potential and strong balance sheet. This program underscores our positive outlook as we continue to advance our mission in interventional oncology.”
Under the program, repurchases may be made from time to time at ma...
|
|
|
14.11.25 - 22:06
|
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to six individuals whose employment commenced in either September 2025 or October 2025.
The grants resulted in the right to purchase 62,500 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The options were granted on October 31, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $9.83, the closing price of Delcath's common stock on October 31, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options ve...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
